Biotech collaboration announces a strategic partnership to develop next-generation delivery approaches for central nervous system therapies. Read for industry implications and commercialization potential.
Key Takeaways
- Nona will use its Harbour Mice HCAb platform to discover BBB-crossing single-domain antibodies
- Lonza will contribute protein development, GS Gene Expression System and GlycoConnect bioconjugation support
- Nona will receive upfront and option payments and revenue sharing from future licenses